Key result
BCR-ABL TKIs, immunotherapies, VEGF inhibitors, and radiation are associated with accelerated atherosclerosis.
Why the study?
While oncologic therapies improve overall survival in patients with malignancy, cardiovascular complications have increased due to shared risk factors and accelerated atherosclerosis caused by the therapies themselves.
Does risk reduction with aspirin and/or statins prevent accelerated atherosclerosis in patients with malignancy exposed to oncologic therapies?
Does risk reduction with aspirin and/or statins prevent accelerated atherosclerosis in patients with malignancy exposed to oncologic therapies?
Certain cancer therapies accelerate atherosclerosis, emphasizing the importance of cardiovascular risk reduction with statins and aspirin in this population.
Warrants vigilance for accelerated atherosclerosis with these therapies; leaves open the need for prospective risk quantification.
PURPOSE OF REVIEW: Recent advances in oncologic therapies have significantly improved overall survival for patients with malignancy. However, cardiovascular complications have not only increased in this population due to shared risk factors and pathophysiology, but also due to the therapies themselves. One key mechanism that warrants further attention is accelerated atherosclerosis due to these agents. RECENT FINDINGS: Here we review recent studies focusing on four classes of anticancer agents with the potential to accelerate atherosclerosis, including breakpoint cluster region-Ableson (BCR-ABL) tyrosine kinase inhibitors, immunotherapies, androgen deprivation therapies, and vascular endothelial growth factor inhibitors. In addition to drug therapy, radiation therapy may also accelerate atherosclerosis. SUMMARY: In order to optimize outcomes for patients with malignancy, enhanced efforts need to focus on mitigating common risk factors, but also recognizing enhanced atherosclerotic risk with certain oncologic therapies. For patients exposed to these agents, risk reduction with agents such as aspirin and/or statins prior to, during, and after cancer treatment may provide opportunities to improve overall outcomes.
No takes yet. Share an insight, caveat, or question.
Reeves et al. (2022) conducted a review in Malignancy. Anticancer agents (BCR-ABL TKIs, immunotherapies, androgen deprivation therapies, VEGF inhibitors) and radiation therapy was evaluated on Accelerated atherosclerosis. Certain oncologic therapies, including BCR-ABL TKIs, immunotherapies, androgen deprivation therapies, VEGF inhibitors, and radiation therapy, have the potential to accelerate atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: